<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220217</url>
  </required_header>
  <id_info>
    <org_study_id>D-FR-01070-002</org_study_id>
    <secondary_id>2016-004928-39</secondary_id>
    <nct_id>NCT03220217</nct_id>
  </id_info>
  <brief_title>To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)</brief_title>
  <official_title>A Multicentre, Randomised, Dose-confirmation, Factorial Phase II Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide&#xD;
      trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to detect&#xD;
      and localize gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). 68Ga-IPN01070 is a&#xD;
      radiolabelled imaging agent to be used in association with Positron-Emission-Tomography&#xD;
      (PET). 68Ga-IPN01070 is made of two main components: 1) IPN01070, an antagonistic&#xD;
      somatostatin analogue which binds to the somatostatin receptor (type 2) present on the&#xD;
      surface of the tumor cells and 2) Gallium-68, a radioisotope that combined with IPN01070 can&#xD;
      be seen in the PET scanner.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2017</start_date>
  <completion_date type="Actual">August 5, 2019</completion_date>
  <primary_completion_date type="Actual">July 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>All the primary and secondary imaging endpoints are read by third-party independent readers. Most of the reading will be conducted in blinded manner.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Lesion Counts Presented by Combination of Injected Peptide/Radioactivity Dose Ranges</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each combination of injected peptide/radioactivity dose range, relative lesion counts were measured as the ratio of the number of lesions detected by 68Ga-satoreotide trizoxetan PET/CT and PET readings to the number of lesions assessed by standard-of-truth (SoT). The SoT in this study was the contrast enhanced (ce)CT scan images acquired at Visit 2 (Day 1) and Visit 3 (Days 16 to 22). Relative lesion counts for PET/CT and PET readings are presented for all organs, primary site of GEP-NET and per organ by each combination of injected peptide/radioactivity dose range after the 1st and 2nd injections.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Lesion Counts Presented by Peptide Mass and Radioactivity Dose Ranges</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each combination of injected peptide/radioactivity dose range, relative lesion counts were measured as the ratio of the number of lesions detected by 68Ga-satoreotide trizoxetan PET/CT and PET readings to the number of lesions assessed by SoT. The SoT in this study was the ceCT scan images acquired at Visit 2 (Day 1) and Visit 3 (Day 16 to 22). Relative lesion counts for PET/CT and PET readings are presented for all organs, primary site of GEP-NET and per organ by both peptide mass range and radioactivity dose range.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Image Quality as Assessed by Tumour-To-Background Ratio Presented by Combination of Injected Peptide/Radioactivity Dose Range</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each PET assessment, image quality was quantitatively measured by the tumour-to-background ratio, obtained using the mean of all lesions tumour-to-backgrounds, for each of the following organs; liver, lymph nodes, bone and lungs. The tumour-to-background ratio was computed by mean standardised uptake value (SUVmean) of the lesion divided by the SUVmean of the subject's reference tissue (tumour-free liver or aortic blood). A high tumour-to-background ratio indicates high effectiveness of 68Ga-satoreotide trizoxetan as a diagnostic agent. Tumour-to-background ratios are presented for primary site of GEP-NET and per organ by each combination of injected peptide/radioactivity dose range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Image Quality as Assessed by Tumour-To-Background Ratio Presented by Peptide Mass and Radioactivity Dose Ranges</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each PET assessment image quality was quantitatively measured by the tumour-to-background ratio, obtained using the mean of all lesions tumour-to-backgrounds, for each of the following organs; liver, lymph nodes, bone and lungs. The tumour-to-background ratio was computed by SUVmean of the lesion divided by the SUVmean of the subject's reference tissue (tumour-free liver or aortic blood). A high tumour-to-background ratio indicates high effectiveness of 68Ga-satoreotide trizoxetan as a diagnostic agent. Tumour-to-background ratios are presented for primary site of GEP-NET and per organ by both peptide mass range and radioactivity dose range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Image Quality as Assessed by Independent Blinded Readers Quality Score</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>A qualitative analysis of the image was assessed by 2 independent blinded readers using a quality score (performed as a back-up to the quantitative quality measured by tumour-to-background analysis). For each PET/CT and PET assessment, each reader performed a direct comparison of the 2 scans from Visit 2 and Visit 3. They noted which scan provided superior images based on overall image quality and lesion count and attributed a score for each assessment. The score for the assessment having superior images was set to &quot;1&quot;, and score for the assessment not selected was set to &quot;0&quot;. In case of equal quality, both assessments had a score of &quot;1&quot;. The image quality score for PET/CT and PET readings as cumulative sum of readers' scores across all subjects by peptide mass and radioactivity dose range combination is presented. Score ranges from 0-16 with higher score indicating more assessments classed as superior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Maximum Standardised Uptake Value (SUVmax) Presented by Combination of Injected Peptide/Radioactivity Dose Ranges</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each PET assessment, SUVmax was measured for each lesion, up to a maximum of 5 most avid lesions per organ that were confirmed by SoT assessment. In order to obtain a unique measure per organ, values of the SUVmax were computed within each of the following organs; liver, lymph nodes, bone and lungs. SUVmax results are presented for primary site of GEP-NET and per organ by each combination of injected peptide/radioactivity dose range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion SUVmax Presented by Peptide Mass and Radioactivity Dose Ranges</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each PET assessment, SUVmax was measured for each lesion, up to a maximum of 5 most avid lesions per organ that are confirmed by SoT assessment. In order to obtain a unique measure per organ, mean of the SUVmax was computed within each of the liver, lymph nodes, bone and lungs. SUVmax results are presented for primary site of GEP-NET and per organ by both peptide mass range and radioactivity dose range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Presented by Combination of Injected Peptide/Radioactivity Dose Range</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each PET/CT and PET assessment, the absolute number of lesions detected by 68Ga-satoreotide trizoxetan were reported for each of the following anatomic sites; primary site of GEP-NET, liver, lymph nodes, axial/appendicular skeleton (bone) and lungs. The absolute number of lesions for PET/CT and PET readings for the 5 anatomic sites are presented by each combination of injected peptide/radioactivity dose range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Presented by Peptide Mass and Radioactivity Dose Ranges</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each PET/CT and PET assessment, the absolute number of lesions detected by 68Ga-satoreotide trizoxetan were reported for each of the following anatomic sites; primary site of GEP-NET, lymph nodes, liver, axial/appendicular skeleton (bone) and lungs. The absolute number of lesions for PET/CT and PET readings for the 5 anatomic sites are presented by both peptide mass range and radioactivity dose range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Compared to Lesions Detected by SoT Presented by Combination of Injected Peptide/Radioactivity Dose Range</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each PET/CT and PET assessment, the number of lesions detected by 68Ga-satoreotide trizoxetan and SoT (ceCT) were reported for each of the following anatomic sites; primary site of GEP-NET, lymph nodes, liver, axial/appendicular skeleton (bone) and lungs. The difference was calculated by number of lesions detected by 68Ga-satoreotide trizoxetan - number of lesions detected by ceCT scan. A positive difference indicates that more lesions were detected by 68Ga-satoreotide trizoxetan than by ceCT scan. A negative difference indicates that more lesions were detected by ceCT scan than by 68Ga-satoreotide trizoxetan. The difference in number of lesions for PET/CT and PET readings for the 5 anatomic sites are presented by each combination of injected peptide/radioactivity dose range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Compared to Lesions Detected by SoT Presented by Peptide Mass and Radioactivity Dose Ranges</measure>
    <time_frame>Day 1 and Days 16 to 22</time_frame>
    <description>For each PET/CT and PET assessment, the number of lesions detected by 68Ga-satoreotide trizoxetan and SoT (ceCT) were reported for each of the following anatomic sites; primary site of GEP-NET, lymph nodes, liver, axial/appendicular skeleton (bone) and lungs. The difference was calculated by number of lesions detected by 68Ga-satoreotide trizoxetan - number of lesions detected by ceCT scan. A positive difference indicates that more lesions were detected by 68Ga-satoreotide trizoxetan than by ceCT scan. A negative difference indicates that more lesions were detected by ceCT scan than by 68Ga-satoreotide trizoxetan. The difference in number of lesions for PET/CT and PET readings for the 5 anatomic sites results are presented by both peptide mass range and radioactivity dose range.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Gastro-Enteropancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>5-20μg/40-80 MBq, 30-45μg/100-140 MBq</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a first intravenous (i.v.) injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 40 to 80 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 100 to 140 MBq.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-20μg/100-140 MBq, 30-45μg/160-200 MBq</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 100 to 140 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 160 to 200 MBq.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-20μg/160-200 MBq, 30-45μg/40-80 MBq</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 160 to 200 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 40 to 80 MBq.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Satoreotide trizoxetan 5-20μg</intervention_name>
    <description>Positron emission tomography (PET) imaging agent</description>
    <arm_group_label>5-20μg/100-140 MBq, 30-45μg/160-200 MBq</arm_group_label>
    <arm_group_label>5-20μg/160-200 MBq, 30-45μg/40-80 MBq</arm_group_label>
    <arm_group_label>5-20μg/40-80 MBq, 30-45μg/100-140 MBq</arm_group_label>
    <other_name>68Ga-OPS202 5-20μg, 68Ga-IPN01070 5-20μg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Satoreotide trizoxetan 30-45μg</intervention_name>
    <description>Positron emission tomography (PET) imaging agent</description>
    <arm_group_label>5-20μg/100-140 MBq, 30-45μg/160-200 MBq</arm_group_label>
    <arm_group_label>5-20μg/160-200 MBq, 30-45μg/40-80 MBq</arm_group_label>
    <arm_group_label>5-20μg/40-80 MBq, 30-45μg/100-140 MBq</arm_group_label>
    <other_name>68Ga-OPS202 30-45μg, 68Ga-IPN01070 30-45μg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed, well differentiated functioning or non-functioning&#xD;
             metastatic GEP-NET (Grade I and II as per World Health Organisation classification&#xD;
             2010)&#xD;
&#xD;
          -  Confirmed presence of somatostatin receptors (type 2) on technically evaluable tumour&#xD;
             lesions documented by a positive Somatostatin Receptor Scan acquired within 6 months&#xD;
             prior to screening (Visit 1) and showing minimally two lesions in at least one of the&#xD;
             key organs; these images shall be available to be sent to the imaging core lab&#xD;
             electronically to ascertain quality and admissibility&#xD;
&#xD;
          -  Body weight between 50 kg (110 lb) and 110 kg (243 lb), inclusive&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fewer than five lesions in total and more than 25 lesions/organ detected by the&#xD;
             previous somatostatin receptor scan in key organs: liver, lymph nodes, bone or lungs&#xD;
&#xD;
          -  Subject who have received treatment of any somatostatin analogue, including&#xD;
             Somatuline® Autogel® /Depot®, Sandostatin® LAR within 28 days, and Sandostatin® within&#xD;
             24 hours prior to first 68Ga-OPS202 administration&#xD;
&#xD;
          -  Prior or planned administration of a radiopharmaceutical within 8 half-lives of the&#xD;
             radionuclide&#xD;
&#xD;
          -  Any condition that precludes the proper performance of PET and/or CT scan: a) Subjects&#xD;
             who are not able to tolerate the CT contrast agent, b) Subjects with metal implants or&#xD;
             arthroplasty, or any other objects that might interfere with the PET and/or CT&#xD;
             analysis, c) Subjects unable to raise arms for prolonged imaging purposes, d) Subjects&#xD;
             unable to lie still for the entire imaging time, e) Subjects weighing greater than 110&#xD;
             kg (243 lb)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic for Radiology and Nuclear Medicine</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <results_first_submitted>October 8, 2020</results_first_submitted>
  <results_first_submitted_qc>January 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2021</results_first_posted>
  <disposition_first_submitted>January 23, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 8, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 14, 2021</disposition_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03220217/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03220217/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This dose-confirmation study was conducted at 4 centres between September 2017 and August 2019. Adult subjects with somatostatin receptor subtype 2 (sstr2)-positive gastroenteropancreatic neuroendocrine tumour (GEP-NET) were randomised to investigational imaging product with Gallium-68 (68Ga)-satoreotide trizoxetan (68Ga-IPN01070, formerly known as 68Ga-OPS202).</recruitment_details>
      <pre_assignment_details>The Screening Visit (Visit 1) was performed within 2 weeks prior to the first 68Ga-satoreotide trizoxetan administration. Subjects' eligibility was re-checked by the investigator at Visit 2 (Day 1) before randomisation to 1 of 3 study arms (A, B or C) with differing 68Ga-satoreotide trizoxetan peptide mass dose and radioactivity dose range combinations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: 5-20 µg/40-80 MBq Then 30-45 µg/100-140 MBq</title>
          <description>Subjects received a single intravenous (i.v.) injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 micrograms (μg) and a radioactivity dose range of 40-80 Megabecquerel (MBq) on Visit 2 (Day 1).&#xD;
After 15 to 21 days at Visit 3 (Days 16 to 22), subjects received a second i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range of 100-140 MBq.&#xD;
Both injections were followed by positron emission tomography(PET)/computed tomography (CT) scan imaging 1 hour post dosing (up to 80 min).</description>
        </group>
        <group group_id="P2">
          <title>Arm B: 5-20 µg/100-140 MBq Then 30-45 µg/160-200 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity dose range of 100-140 MBq on Visit 2 (Day 1).&#xD;
After 15 to 21 days at Visit 3 (Days 16 to 22), subjects received a second i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range of 160-200 MBq.&#xD;
Both injections were followed by PET/CT scan imaging 1 hour post dosing (up to 80 min).</description>
        </group>
        <group group_id="P3">
          <title>Arm C: 5-20 µg/160-200 MBq Then 30-45 µg/40-80 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity dose range of 160-200 MBq on Visit 2 (Day 1).&#xD;
After 15 to 21 days at Visit 3 (Days 16 to 22), subjects received a second i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass of 30-45 μg and a radioactivity range of 40-80 MBq.&#xD;
Both injections were followed by PET/CT scan imaging 1 hour post dosing (up to 80 min).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Missed Procedure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The randomised population included all subjects randomly assigned to a dosing arm/sequence.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: 5-20 µg/40-80 MBq Then 30-45 µg/100-140 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity dose range of 40-80 MBq on Visit 2 (Day 1).&#xD;
After 15 to 21 days at Visit 3 (Days 16 to 22), subjects received a second i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range of 100-140 MBq.&#xD;
Both injections were followed by PET/CT scan imaging 1 hour post dosing (up to 80 min).</description>
        </group>
        <group group_id="B2">
          <title>Arm B: 5-20 µg/100-140 MBq Then 30-45 µg/160-200 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity dose range of 100-140 MBq on Visit 2 (Day 1).&#xD;
After 15 to 21 days at Visit 3 (Days 16 to 22), subjects received a second i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range of 160-200 MBq.&#xD;
Both injections were followed by PET/CT scan imaging 1 hour post dosing (up to 80 min).</description>
        </group>
        <group group_id="B3">
          <title>Arm C: 5-20 µg/160-200 MBq Then 30-45 µg/40-80 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity dose range of 160-200 MBq on Visit 2 (Day 1).&#xD;
After 15 to 21 days at Visit 3 (Days 16 to 22), subjects received a second i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 40-80 MBq.&#xD;
Both injections were followed by PET/CT scan imaging 1 hour post dosing (up to 80 min).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="11.1"/>
                    <measurement group_id="B2" value="67.6" spread="6.4"/>
                    <measurement group_id="B3" value="60.7" spread="12.3"/>
                    <measurement group_id="B4" value="65.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Lesion Counts Presented by Combination of Injected Peptide/Radioactivity Dose Ranges</title>
        <description>For each combination of injected peptide/radioactivity dose range, relative lesion counts were measured as the ratio of the number of lesions detected by 68Ga-satoreotide trizoxetan PET/CT and PET readings to the number of lesions assessed by standard-of-truth (SoT). The SoT in this study was the contrast enhanced (ce)CT scan images acquired at Visit 2 (Day 1) and Visit 3 (Days 16 to 22). Relative lesion counts for PET/CT and PET readings are presented for all organs, primary site of GEP-NET and per organ by each combination of injected peptide/radioactivity dose range after the 1st and 2nd injections.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the Per Protocol (PP) population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: 5-20 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass of 5-20 μg and a radioactivity range of 40-80 MBq on Visit 2/Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Arm A: 30-45 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass of 30-45 μg and a radioactivity range of 100-140 MBq on Visit 3/Days 16 to 22.</description>
          </group>
          <group group_id="O3">
            <title>Arm B: 5-20 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass of 5-20 μg and a radioactivity range of 100-140 MBq on Visit 2/Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Arm B: 30-45 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass of 30-45 μg and a radioactivity range of 160-200 MBq on Visit 3/Days 16 to 22.</description>
          </group>
          <group group_id="O5">
            <title>Arm C: 5-20 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass of 5-20 μg and a radioactivity range of 160-200 MBq on Visit 2/Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Arm C: 30-45 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass of 30-45 μg and a radioactivity range of 40-80 MBq on Visit 3/Days 16 to 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Lesion Counts Presented by Combination of Injected Peptide/Radioactivity Dose Ranges</title>
          <description>For each combination of injected peptide/radioactivity dose range, relative lesion counts were measured as the ratio of the number of lesions detected by 68Ga-satoreotide trizoxetan PET/CT and PET readings to the number of lesions assessed by standard-of-truth (SoT). The SoT in this study was the contrast enhanced (ce)CT scan images acquired at Visit 2 (Day 1) and Visit 3 (Days 16 to 22). Relative lesion counts for PET/CT and PET readings are presented for all organs, primary site of GEP-NET and per organ by each combination of injected peptide/radioactivity dose range after the 1st and 2nd injections.</description>
          <population>Results are presented for the Per Protocol (PP) population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET/CT: All Organs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.73" upper_limit="15.00"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.71" upper_limit="13.50"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.64" upper_limit="4.41"/>
                    <measurement group_id="O4" value="2.6" lower_limit="0.82" upper_limit="5.25"/>
                    <measurement group_id="O5" value="2.7" lower_limit="0.91" upper_limit="16.25"/>
                    <measurement group_id="O6" value="2.5" lower_limit="0.82" upper_limit="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O6" value="1.0" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.73" upper_limit="9.00"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.9" lower_limit="0.83" upper_limit="8.00"/>
                    <measurement group_id="O4" value="3.5" lower_limit="1.50" upper_limit="11.00"/>
                    <measurement group_id="O5" value="2.4" lower_limit="0.86" upper_limit="7.5"/>
                    <measurement group_id="O6" value="2.6" lower_limit="0.76" upper_limit="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.80" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.40" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.00" upper_limit="12.00"/>
                    <measurement group_id="O5" value="2.2" lower_limit="1.25" upper_limit="5.00"/>
                    <measurement group_id="O6" value="1.6" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.6" lower_limit="4.6" upper_limit="4.6"/>
                    <measurement group_id="O4" value="3.6" lower_limit="3.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.5" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: All Organs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.73" upper_limit="19.00"/>
                    <measurement group_id="O2" value="3.9" lower_limit="1.00" upper_limit="14.50"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.00" upper_limit="4.50"/>
                    <measurement group_id="O4" value="2.6" lower_limit="1.50" upper_limit="4.75"/>
                    <measurement group_id="O5" value="2.8" lower_limit="0.91" upper_limit="13.50"/>
                    <measurement group_id="O6" value="2.7" lower_limit="0.68" upper_limit="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O6" value="1.0" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.73" upper_limit="5.00"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.00" upper_limit="7.00"/>
                    <measurement group_id="O3" value="2.9" lower_limit="0.67" upper_limit="7.00"/>
                    <measurement group_id="O4" value="3.4" lower_limit="1.33" upper_limit="9.00"/>
                    <measurement group_id="O5" value="2.4" lower_limit="0.86" upper_limit="7.00"/>
                    <measurement group_id="O6" value="2.3" lower_limit="0.62" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.80" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.60" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.2" lower_limit="0.50" upper_limit="10.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0.50" upper_limit="14.00"/>
                    <measurement group_id="O5" value="3.8" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="3.1" lower_limit="0.75" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.6" lower_limit="3.6" upper_limit="3.6"/>
                    <measurement group_id="O4" value="3.8" lower_limit="3.8" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.5" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.5" lower_limit="0.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relative Lesion Counts Presented by Peptide Mass and Radioactivity Dose Ranges</title>
        <description>For each combination of injected peptide/radioactivity dose range, relative lesion counts were measured as the ratio of the number of lesions detected by 68Ga-satoreotide trizoxetan PET/CT and PET readings to the number of lesions assessed by SoT. The SoT in this study was the ceCT scan images acquired at Visit 2 (Day 1) and Visit 3 (Day 16 to 22). Relative lesion counts for PET/CT and PET readings are presented for all organs, primary site of GEP-NET and per organ by both peptide mass range and radioactivity dose range.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peptide Mass Dose Range 5-20 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O2">
            <title>Peptide Mass Dose Range 30-45 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O3">
            <title>Radioactivity Dose Range 40-80 MBq</title>
            <description>Subjects from Arms A and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose of 40-80 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O4">
            <title>Radioactivity Dose Range 100-140 MBq</title>
            <description>Subjects from Arms A and B who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 100-140 MBq on either Visit 2(Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O5">
            <title>Radioactivity Dose Range 160-200 MBq</title>
            <description>Subjects from Arms B and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 160-200 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Lesion Counts Presented by Peptide Mass and Radioactivity Dose Ranges</title>
          <description>For each combination of injected peptide/radioactivity dose range, relative lesion counts were measured as the ratio of the number of lesions detected by 68Ga-satoreotide trizoxetan PET/CT and PET readings to the number of lesions assessed by SoT. The SoT in this study was the ceCT scan images acquired at Visit 2 (Day 1) and Visit 3 (Day 16 to 22). Relative lesion counts for PET/CT and PET readings are presented for all organs, primary site of GEP-NET and per organ by both peptide mass range and radioactivity dose range.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET/CT: All Organs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.64" upper_limit="16.25"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.82" upper_limit="13.50"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.73" upper_limit="15.00"/>
                    <measurement group_id="O4" value="2.6" lower_limit="0.64" upper_limit="13.50"/>
                    <measurement group_id="O5" value="2.6" lower_limit="0.82" upper_limit="16.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.73" upper_limit="9.00"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.76" upper_limit="11.00"/>
                    <measurement group_id="O3" value="2.2" lower_limit="0.73" upper_limit="9.00"/>
                    <measurement group_id="O4" value="3.0" lower_limit="0.83" upper_limit="8.00"/>
                    <measurement group_id="O5" value="2.7" lower_limit="0.86" upper_limit="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.00" upper_limit="12.00"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="1.3" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O5" value="1.3" lower_limit="0.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="4.6" upper_limit="4.6"/>
                    <measurement group_id="O2" value="3.6" lower_limit="3.6" upper_limit="3.6"/>
                    <measurement group_id="O4" value="4.6" lower_limit="4.6" upper_limit="4.6"/>
                    <measurement group_id="O5" value="3.6" lower_limit="3.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: All Organs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.73" upper_limit="19.00"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.68" upper_limit="14.50"/>
                    <measurement group_id="O3" value="2.6" lower_limit="0.68" upper_limit="19.00"/>
                    <measurement group_id="O4" value="2.8" lower_limit="1.00" upper_limit="14.50"/>
                    <measurement group_id="O5" value="2.7" lower_limit="0.91" upper_limit="13.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.67" upper_limit="7.00"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.62" upper_limit="9.00"/>
                    <measurement group_id="O3" value="2.6" lower_limit="0.62" upper_limit="6.00"/>
                    <measurement group_id="O4" value="3.3" lower_limit="0.67" upper_limit="7.00"/>
                    <measurement group_id="O5" value="2.8" lower_limit="0.86" upper_limit="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.50" upper_limit="10.00"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.50" upper_limit="14.00"/>
                    <measurement group_id="O3" value="2.7" lower_limit="0.75" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0.50" upper_limit="10.00"/>
                    <measurement group_id="O5" value="2.2" lower_limit="0.50" upper_limit="14.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="3.6" upper_limit="3.6"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.8" upper_limit="3.8"/>
                    <measurement group_id="O4" value="3.6" lower_limit="3.6" upper_limit="3.6"/>
                    <measurement group_id="O5" value="3.8" lower_limit="3.8" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.5" lower_limit="0.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Image Quality as Assessed by Tumour-To-Background Ratio Presented by Combination of Injected Peptide/Radioactivity Dose Range</title>
        <description>For each PET assessment, image quality was quantitatively measured by the tumour-to-background ratio, obtained using the mean of all lesions tumour-to-backgrounds, for each of the following organs; liver, lymph nodes, bone and lungs. The tumour-to-background ratio was computed by mean standardised uptake value (SUVmean) of the lesion divided by the SUVmean of the subject's reference tissue (tumour-free liver or aortic blood). A high tumour-to-background ratio indicates high effectiveness of 68Ga-satoreotide trizoxetan as a diagnostic agent. Tumour-to-background ratios are presented for primary site of GEP-NET and per organ by each combination of injected peptide/radioactivity dose range.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: 5-20 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 40-80 MBq on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O2">
            <title>Arm A: 30-45 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 100-140 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
          <group group_id="O3">
            <title>Arm B: 5-20 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 100-140 MBq on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O4">
            <title>Arm B: 30-45 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 160-200 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
          <group group_id="O5">
            <title>Arm C: 5-20 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 160-200 MBq.</description>
          </group>
          <group group_id="O6">
            <title>Arm C: 30-45 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 40-80 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
        </group_list>
        <measure>
          <title>Image Quality as Assessed by Tumour-To-Background Ratio Presented by Combination of Injected Peptide/Radioactivity Dose Range</title>
          <description>For each PET assessment, image quality was quantitatively measured by the tumour-to-background ratio, obtained using the mean of all lesions tumour-to-backgrounds, for each of the following organs; liver, lymph nodes, bone and lungs. The tumour-to-background ratio was computed by mean standardised uptake value (SUVmean) of the lesion divided by the SUVmean of the subject's reference tissue (tumour-free liver or aortic blood). A high tumour-to-background ratio indicates high effectiveness of 68Ga-satoreotide trizoxetan as a diagnostic agent. Tumour-to-background ratios are presented for primary site of GEP-NET and per organ by each combination of injected peptide/radioactivity dose range.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" lower_limit="7.04" upper_limit="45.84"/>
                    <measurement group_id="O2" value="17.5" lower_limit="7.07" upper_limit="27.87"/>
                    <measurement group_id="O3" value="4.8" lower_limit="4.57" upper_limit="33.81"/>
                    <measurement group_id="O4" value="18.1" lower_limit="3.29" upper_limit="32.81"/>
                    <measurement group_id="O5" value="2.3" lower_limit="2.3" upper_limit="2.3"/>
                    <measurement group_id="O6" value="2.2" lower_limit="2.2" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="3.75" upper_limit="12.88"/>
                    <measurement group_id="O2" value="4.7" lower_limit="3.56" upper_limit="9.96"/>
                    <measurement group_id="O3" value="4.2" lower_limit="3.10" upper_limit="24.95"/>
                    <measurement group_id="O4" value="4.2" lower_limit="3.05" upper_limit="29.33"/>
                    <measurement group_id="O5" value="3.6" lower_limit="2.13" upper_limit="10.75"/>
                    <measurement group_id="O6" value="4.0" lower_limit="3.07" upper_limit="22.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="3.87" upper_limit="16.98"/>
                    <measurement group_id="O2" value="6.2" lower_limit="3.22" upper_limit="13.76"/>
                    <measurement group_id="O3" value="5.1" lower_limit="2.55" upper_limit="16.10"/>
                    <measurement group_id="O4" value="8.2" lower_limit="1.54" upper_limit="13.70"/>
                    <measurement group_id="O5" value="5.7" lower_limit="3.40" upper_limit="12.84"/>
                    <measurement group_id="O6" value="4.5" lower_limit="3.50" upper_limit="18.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="12.7" lower_limit="12.7" upper_limit="12.7"/>
                    <measurement group_id="O4" value="9.2" lower_limit="9.2" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1.1" lower_limit="1.1" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Image Quality as Assessed by Tumour-To-Background Ratio Presented by Peptide Mass and Radioactivity Dose Ranges</title>
        <description>For each PET assessment image quality was quantitatively measured by the tumour-to-background ratio, obtained using the mean of all lesions tumour-to-backgrounds, for each of the following organs; liver, lymph nodes, bone and lungs. The tumour-to-background ratio was computed by SUVmean of the lesion divided by the SUVmean of the subject's reference tissue (tumour-free liver or aortic blood). A high tumour-to-background ratio indicates high effectiveness of 68Ga-satoreotide trizoxetan as a diagnostic agent. Tumour-to-background ratios are presented for primary site of GEP-NET and per organ by both peptide mass range and radioactivity dose range.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peptide Mass Dose Range 5-20 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O2">
            <title>Peptide Mass Dose Range 30-45 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O3">
            <title>Radioactivity Dose Range 40-80 MBq</title>
            <description>Subjects from Arms A and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose of 40-80 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O4">
            <title>Radioactivity Dose Range 100-140 MBq</title>
            <description>Subjects from Arms A and B who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 100-140 MBq on either Visit 2(Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O5">
            <title>Radioactivity Dose Range 160-200 MBq</title>
            <description>Subjects from Arms B and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 160-200 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
        </group_list>
        <measure>
          <title>Image Quality as Assessed by Tumour-To-Background Ratio Presented by Peptide Mass and Radioactivity Dose Ranges</title>
          <description>For each PET assessment image quality was quantitatively measured by the tumour-to-background ratio, obtained using the mean of all lesions tumour-to-backgrounds, for each of the following organs; liver, lymph nodes, bone and lungs. The tumour-to-background ratio was computed by SUVmean of the lesion divided by the SUVmean of the subject's reference tissue (tumour-free liver or aortic blood). A high tumour-to-background ratio indicates high effectiveness of 68Ga-satoreotide trizoxetan as a diagnostic agent. Tumour-to-background ratios are presented for primary site of GEP-NET and per organ by both peptide mass range and radioactivity dose range.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="2.28" upper_limit="45.84"/>
                    <measurement group_id="O2" value="7.1" lower_limit="2.22" upper_limit="32.81"/>
                    <measurement group_id="O3" value="7.0" lower_limit="2.22" upper_limit="45.84"/>
                    <measurement group_id="O4" value="7.1" lower_limit="4.57" upper_limit="33.81"/>
                    <measurement group_id="O5" value="3.3" lower_limit="2.28" upper_limit="32.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.13" upper_limit="24.95"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.05" upper_limit="29.33"/>
                    <measurement group_id="O3" value="4.3" lower_limit="3.07" upper_limit="22.48"/>
                    <measurement group_id="O4" value="4.4" lower_limit="3.10" upper_limit="24.95"/>
                    <measurement group_id="O5" value="4.1" lower_limit="2.13" upper_limit="29.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2.55" upper_limit="16.98"/>
                    <measurement group_id="O2" value="5.2" lower_limit="1.54" upper_limit="18.69"/>
                    <measurement group_id="O3" value="4.9" lower_limit="3.50" upper_limit="18.69"/>
                    <measurement group_id="O4" value="5.3" lower_limit="2.55" upper_limit="16.10"/>
                    <measurement group_id="O5" value="5.7" lower_limit="1.54" upper_limit="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="12.7" upper_limit="12.7"/>
                    <measurement group_id="O2" value="9.2" lower_limit="9.2" upper_limit="9.2"/>
                    <measurement group_id="O4" value="12.7" lower_limit="12.7" upper_limit="12.7"/>
                    <measurement group_id="O5" value="9.2" lower_limit="9.2" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.1" upper_limit="1.1"/>
                    <measurement group_id="O5" value="1.1" lower_limit="1.1" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Image Quality as Assessed by Independent Blinded Readers Quality Score</title>
        <description>A qualitative analysis of the image was assessed by 2 independent blinded readers using a quality score (performed as a back-up to the quantitative quality measured by tumour-to-background analysis). For each PET/CT and PET assessment, each reader performed a direct comparison of the 2 scans from Visit 2 and Visit 3. They noted which scan provided superior images based on overall image quality and lesion count and attributed a score for each assessment. The score for the assessment having superior images was set to &quot;1&quot;, and score for the assessment not selected was set to &quot;0&quot;. In case of equal quality, both assessments had a score of &quot;1&quot;. The image quality score for PET/CT and PET readings as cumulative sum of readers' scores across all subjects by peptide mass and radioactivity dose range combination is presented. Score ranges from 0-16 with higher score indicating more assessments classed as superior.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis. Note: image scores are presented as the cumulative sum of both readers' results across all subjects analysed per specified combination/visit; they do not represent summarised values.</population>
        <group_list>
          <group group_id="O1">
            <title>Radioactivity Dose Range 40-80 MBq</title>
            <description>Subjects from Arms A and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose of 40-80 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O2">
            <title>Radioactivity Dose Range 100-140 MBq</title>
            <description>Subjects from Arms A and B who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 100-140 MBq on either Visit 2(Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O3">
            <title>Radioactivity Dose Range 160-200 MBq</title>
            <description>Subjects from Arms B and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 160-200 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
        </group_list>
        <measure>
          <title>Image Quality as Assessed by Independent Blinded Readers Quality Score</title>
          <description>A qualitative analysis of the image was assessed by 2 independent blinded readers using a quality score (performed as a back-up to the quantitative quality measured by tumour-to-background analysis). For each PET/CT and PET assessment, each reader performed a direct comparison of the 2 scans from Visit 2 and Visit 3. They noted which scan provided superior images based on overall image quality and lesion count and attributed a score for each assessment. The score for the assessment having superior images was set to &quot;1&quot;, and score for the assessment not selected was set to &quot;0&quot;. In case of equal quality, both assessments had a score of &quot;1&quot;. The image quality score for PET/CT and PET readings as cumulative sum of readers' scores across all subjects by peptide mass and radioactivity dose range combination is presented. Score ranges from 0-16 with higher score indicating more assessments classed as superior.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis. Note: image scores are presented as the cumulative sum of both readers' results across all subjects analysed per specified combination/visit; they do not represent summarised values.</population>
          <units>Cumulative Sum of Readers' Scores</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET/CT: Peptide mass 5-20 μg (Visit 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Peptide mass 30-45 μg (Visit 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Peptide mass 5-20 μg (Visit 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Peptide mass 30-45 μg (Visit 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Maximum Standardised Uptake Value (SUVmax) Presented by Combination of Injected Peptide/Radioactivity Dose Ranges</title>
        <description>For each PET assessment, SUVmax was measured for each lesion, up to a maximum of 5 most avid lesions per organ that were confirmed by SoT assessment. In order to obtain a unique measure per organ, values of the SUVmax were computed within each of the following organs; liver, lymph nodes, bone and lungs. SUVmax results are presented for primary site of GEP-NET and per organ by each combination of injected peptide/radioactivity dose range.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: 5-20 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 40-80 MBq on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O2">
            <title>Arm A: 30-45 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 100-140 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
          <group group_id="O3">
            <title>Arm B: 5-20 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 100-140 MBq on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O4">
            <title>Arm B: 30-45 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 160-200 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
          <group group_id="O5">
            <title>Arm C: 5-20 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 160-200 MBq.</description>
          </group>
          <group group_id="O6">
            <title>Arm C: 30-45 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 40-80 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Maximum Standardised Uptake Value (SUVmax) Presented by Combination of Injected Peptide/Radioactivity Dose Ranges</title>
          <description>For each PET assessment, SUVmax was measured for each lesion, up to a maximum of 5 most avid lesions per organ that were confirmed by SoT assessment. In order to obtain a unique measure per organ, values of the SUVmax were computed within each of the following organs; liver, lymph nodes, bone and lungs. SUVmax results are presented for primary site of GEP-NET and per organ by each combination of injected peptide/radioactivity dose range.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>SUV</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" lower_limit="44.63" upper_limit="136.04"/>
                    <measurement group_id="O2" value="90.3" lower_limit="43.34" upper_limit="137.34"/>
                    <measurement group_id="O3" value="24.5" lower_limit="16.66" upper_limit="86.71"/>
                    <measurement group_id="O4" value="48.9" lower_limit="11.93" upper_limit="85.78"/>
                    <measurement group_id="O5" value="14.2" lower_limit="14.2" upper_limit="14.2"/>
                    <measurement group_id="O6" value="13.7" lower_limit="13.7" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" lower_limit="18.25" upper_limit="49.16"/>
                    <measurement group_id="O2" value="22.9" lower_limit="18.01" upper_limit="59.83"/>
                    <measurement group_id="O3" value="9.5" lower_limit="6.74" upper_limit="63.68"/>
                    <measurement group_id="O4" value="16.0" lower_limit="9.56" upper_limit="78.43"/>
                    <measurement group_id="O5" value="12.4" lower_limit="6.95" upper_limit="30.07"/>
                    <measurement group_id="O6" value="17.7" lower_limit="10.62" upper_limit="30.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="19.52" upper_limit="40.74"/>
                    <measurement group_id="O2" value="35.7" lower_limit="16.69" upper_limit="41.11"/>
                    <measurement group_id="O3" value="28.5" lower_limit="9.03" upper_limit="83.06"/>
                    <measurement group_id="O4" value="27.7" lower_limit="5.25" upper_limit="53.79"/>
                    <measurement group_id="O5" value="13.8" lower_limit="6.08" upper_limit="21.73"/>
                    <measurement group_id="O6" value="12.7" lower_limit="6.15" upper_limit="21.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="57.5" lower_limit="57.5" upper_limit="57.5"/>
                    <measurement group_id="O4" value="36.5" lower_limit="36.5" upper_limit="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1.8" lower_limit="1.8" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion SUVmax Presented by Peptide Mass and Radioactivity Dose Ranges</title>
        <description>For each PET assessment, SUVmax was measured for each lesion, up to a maximum of 5 most avid lesions per organ that are confirmed by SoT assessment. In order to obtain a unique measure per organ, mean of the SUVmax was computed within each of the liver, lymph nodes, bone and lungs. SUVmax results are presented for primary site of GEP-NET and per organ by both peptide mass range and radioactivity dose range.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peptide Mass Dose Range 5-20 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O2">
            <title>Peptide Mass Dose Range 30-45 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O3">
            <title>Radioactivity Dose Range 40-80 MBq</title>
            <description>Subjects from Arms A and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose of 40-80 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O4">
            <title>Radioactivity Dose Range 100-140 MBq</title>
            <description>Subjects from Arms A and B who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 100-140 MBq on either Visit 2(Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O5">
            <title>Radioactivity Dose Range 160-200 MBq</title>
            <description>Subjects from Arms B and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 160-200 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion SUVmax Presented by Peptide Mass and Radioactivity Dose Ranges</title>
          <description>For each PET assessment, SUVmax was measured for each lesion, up to a maximum of 5 most avid lesions per organ that are confirmed by SoT assessment. In order to obtain a unique measure per organ, mean of the SUVmax was computed within each of the liver, lymph nodes, bone and lungs. SUVmax results are presented for primary site of GEP-NET and per organ by both peptide mass range and radioactivity dose range.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>SUV</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="14.19" upper_limit="136.04"/>
                    <measurement group_id="O2" value="43.3" lower_limit="11.93" upper_limit="137.34"/>
                    <measurement group_id="O3" value="44.6" lower_limit="13.67" upper_limit="136.04"/>
                    <measurement group_id="O4" value="43.3" lower_limit="16.66" upper_limit="137.34"/>
                    <measurement group_id="O5" value="14.2" lower_limit="11.93" upper_limit="85.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="6.74" upper_limit="63.68"/>
                    <measurement group_id="O2" value="21.1" lower_limit="9.56" upper_limit="78.43"/>
                    <measurement group_id="O3" value="20.0" lower_limit="10.62" upper_limit="49.16"/>
                    <measurement group_id="O4" value="20.1" lower_limit="6.74" upper_limit="63.68"/>
                    <measurement group_id="O5" value="13.3" lower_limit="6.95" upper_limit="78.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" lower_limit="6.08" upper_limit="83.06"/>
                    <measurement group_id="O2" value="20.3" lower_limit="5.25" upper_limit="53.79"/>
                    <measurement group_id="O3" value="20.4" lower_limit="6.15" upper_limit="40.74"/>
                    <measurement group_id="O4" value="32.6" lower_limit="9.03" upper_limit="83.06"/>
                    <measurement group_id="O5" value="18.6" lower_limit="5.25" upper_limit="53.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" lower_limit="57.5" upper_limit="57.5"/>
                    <measurement group_id="O2" value="36.5" lower_limit="36.5" upper_limit="36.5"/>
                    <measurement group_id="O4" value="57.5" lower_limit="57.5" upper_limit="57.5"/>
                    <measurement group_id="O5" value="36.5" lower_limit="36.5" upper_limit="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.8" upper_limit="1.8"/>
                    <measurement group_id="O5" value="1.8" lower_limit="1.8" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Presented by Combination of Injected Peptide/Radioactivity Dose Range</title>
        <description>For each PET/CT and PET assessment, the absolute number of lesions detected by 68Ga-satoreotide trizoxetan were reported for each of the following anatomic sites; primary site of GEP-NET, liver, lymph nodes, axial/appendicular skeleton (bone) and lungs. The absolute number of lesions for PET/CT and PET readings for the 5 anatomic sites are presented by each combination of injected peptide/radioactivity dose range.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: 5-20 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 40-80 MBq on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O2">
            <title>Arm A: 30-45 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 100-140 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
          <group group_id="O3">
            <title>Arm B: 5-20 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 100-140 MBq on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O4">
            <title>Arm B: 30-45 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 160-200 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
          <group group_id="O5">
            <title>Arm C: 5-20 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 160-200 MBq.</description>
          </group>
          <group group_id="O6">
            <title>Arm C: 30-45 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 40-80 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Presented by Combination of Injected Peptide/Radioactivity Dose Range</title>
          <description>For each PET/CT and PET assessment, the absolute number of lesions detected by 68Ga-satoreotide trizoxetan were reported for each of the following anatomic sites; primary site of GEP-NET, liver, lymph nodes, axial/appendicular skeleton (bone) and lungs. The absolute number of lesions for PET/CT and PET readings for the 5 anatomic sites are presented by each combination of injected peptide/radioactivity dose range.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>Lesions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET/CT: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O6" value="1.0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="O2" value="12.5" lower_limit="3" upper_limit="22"/>
                    <measurement group_id="O3" value="8.0" lower_limit="0" upper_limit="19"/>
                    <measurement group_id="O4" value="11.0" lower_limit="0" upper_limit="21"/>
                    <measurement group_id="O5" value="14.5" lower_limit="3" upper_limit="71"/>
                    <measurement group_id="O6" value="14.5" lower_limit="3" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O3" value="4.0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O5" value="6.0" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O6" value="3.5" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="55"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1" upper_limit="43"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O6" value="3.0" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O6" value="1.0" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="3" upper_limit="22"/>
                    <measurement group_id="O2" value="9.0" lower_limit="3" upper_limit="23"/>
                    <measurement group_id="O3" value="8.0" lower_limit="0" upper_limit="25"/>
                    <measurement group_id="O4" value="13.0" lower_limit="0" upper_limit="26"/>
                    <measurement group_id="O5" value="14.0" lower_limit="3" upper_limit="76"/>
                    <measurement group_id="O6" value="11.0" lower_limit="3" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O3" value="3.0" lower_limit="0" upper_limit="21"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0" upper_limit="18"/>
                    <measurement group_id="O5" value="6.5" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O6" value="4.5" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="43"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0" upper_limit="46"/>
                    <measurement group_id="O5" value="3.5" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O6" value="3.0" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Presented by Peptide Mass and Radioactivity Dose Ranges</title>
        <description>For each PET/CT and PET assessment, the absolute number of lesions detected by 68Ga-satoreotide trizoxetan were reported for each of the following anatomic sites; primary site of GEP-NET, lymph nodes, liver, axial/appendicular skeleton (bone) and lungs. The absolute number of lesions for PET/CT and PET readings for the 5 anatomic sites are presented by both peptide mass range and radioactivity dose range.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peptide Mass Dose Range 5-20 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O2">
            <title>Peptide Mass Dose Range 30-45 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O3">
            <title>Radioactivity Dose Range 40-80 MBq</title>
            <description>Subjects from Arms A and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose of 40-80 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O4">
            <title>Radioactivity Dose Range 100-140 MBq</title>
            <description>Subjects from Arms A and B who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 100-140 MBq on either Visit 2(Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O5">
            <title>Radioactivity Dose Range 160-200 MBq</title>
            <description>Subjects from Arms B and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 160-200 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Presented by Peptide Mass and Radioactivity Dose Ranges</title>
          <description>For each PET/CT and PET assessment, the absolute number of lesions detected by 68Ga-satoreotide trizoxetan were reported for each of the following anatomic sites; primary site of GEP-NET, lymph nodes, liver, axial/appendicular skeleton (bone) and lungs. The absolute number of lesions for PET/CT and PET readings for the 5 anatomic sites are presented by both peptide mass range and radioactivity dose range.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>Lesions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET/CT: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="0" upper_limit="71"/>
                    <measurement group_id="O2" value="13.0" lower_limit="0" upper_limit="93"/>
                    <measurement group_id="O3" value="11.5" lower_limit="3" upper_limit="93"/>
                    <measurement group_id="O4" value="11.0" lower_limit="0" upper_limit="22"/>
                    <measurement group_id="O5" value="11.0" lower_limit="0" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O3" value="4.0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O5" value="4.0" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="55"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1" upper_limit="43"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0" upper_limit="55"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="0" upper_limit="76"/>
                    <measurement group_id="O2" value="11.0" lower_limit="0" upper_limit="78"/>
                    <measurement group_id="O3" value="10.0" lower_limit="3" upper_limit="78"/>
                    <measurement group_id="O4" value="8.0" lower_limit="0" upper_limit="25"/>
                    <measurement group_id="O5" value="13.0" lower_limit="0" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="0" upper_limit="21"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0" upper_limit="18"/>
                    <measurement group_id="O3" value="4.0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O4" value="3.5" lower_limit="0" upper_limit="21"/>
                    <measurement group_id="O5" value="6.0" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0" upper_limit="43"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="46"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0" upper_limit="43"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Compared to Lesions Detected by SoT Presented by Combination of Injected Peptide/Radioactivity Dose Range</title>
        <description>For each PET/CT and PET assessment, the number of lesions detected by 68Ga-satoreotide trizoxetan and SoT (ceCT) were reported for each of the following anatomic sites; primary site of GEP-NET, lymph nodes, liver, axial/appendicular skeleton (bone) and lungs. The difference was calculated by number of lesions detected by 68Ga-satoreotide trizoxetan - number of lesions detected by ceCT scan. A positive difference indicates that more lesions were detected by 68Ga-satoreotide trizoxetan than by ceCT scan. A negative difference indicates that more lesions were detected by ceCT scan than by 68Ga-satoreotide trizoxetan. The difference in number of lesions for PET/CT and PET readings for the 5 anatomic sites are presented by each combination of injected peptide/radioactivity dose range.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: 5-20 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 40-80 MBq on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O2">
            <title>Arm A: 30-45 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 100-140 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
          <group group_id="O3">
            <title>Arm B: 5-20 μg/100-140 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 100-140 MBq on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O4">
            <title>Arm B: 30-45 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 160-200 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
          <group group_id="O5">
            <title>Arm C: 5-20 μg/160-200 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 160-200 MBq.</description>
          </group>
          <group group_id="O6">
            <title>Arm C: 30-45 μg/40-80 MBq</title>
            <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 40-80 MBq on Visit 3 (Days 16 to 22).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Compared to Lesions Detected by SoT Presented by Combination of Injected Peptide/Radioactivity Dose Range</title>
          <description>For each PET/CT and PET assessment, the number of lesions detected by 68Ga-satoreotide trizoxetan and SoT (ceCT) were reported for each of the following anatomic sites; primary site of GEP-NET, lymph nodes, liver, axial/appendicular skeleton (bone) and lungs. The difference was calculated by number of lesions detected by 68Ga-satoreotide trizoxetan - number of lesions detected by ceCT scan. A positive difference indicates that more lesions were detected by 68Ga-satoreotide trizoxetan than by ceCT scan. A negative difference indicates that more lesions were detected by ceCT scan than by 68Ga-satoreotide trizoxetan. The difference in number of lesions for PET/CT and PET readings for the 5 anatomic sites are presented by each combination of injected peptide/radioactivity dose range.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>Lesions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET/CT: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O5" value="0.5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="-3" upper_limit="13"/>
                    <measurement group_id="O2" value="9.0" lower_limit="3" upper_limit="14"/>
                    <measurement group_id="O3" value="8.0" lower_limit="-1" upper_limit="19"/>
                    <measurement group_id="O4" value="10.0" lower_limit="0" upper_limit="21"/>
                    <measurement group_id="O5" value="4.0" lower_limit="-3" upper_limit="53"/>
                    <measurement group_id="O6" value="5.5" lower_limit="-5" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-3" upper_limit="4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-3" upper_limit="7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-2" upper_limit="11"/>
                    <measurement group_id="O5" value="3.0" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O6" value="1.0" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="43"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1" upper_limit="31"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O6" value="3.0" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O6" value="1.0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="-3" upper_limit="22"/>
                    <measurement group_id="O2" value="5.5" lower_limit="0" upper_limit="21"/>
                    <measurement group_id="O3" value="8.0" lower_limit="-2" upper_limit="25"/>
                    <measurement group_id="O4" value="11.0" lower_limit="0" upper_limit="26"/>
                    <measurement group_id="O5" value="5.0" lower_limit="-3" upper_limit="58"/>
                    <measurement group_id="O6" value="5.0" lower_limit="-8" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O3" value="1.0" lower_limit="-2" upper_limit="18"/>
                    <measurement group_id="O4" value="1.0" lower_limit="-2" upper_limit="13"/>
                    <measurement group_id="O5" value="5.5" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O6" value="4.5" lower_limit="-1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="31"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0" upper_limit="34"/>
                    <measurement group_id="O5" value="3.5" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O6" value="3.0" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O4" value="2.0" lower_limit="-1" upper_limit="4"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Compared to Lesions Detected by SoT Presented by Peptide Mass and Radioactivity Dose Ranges</title>
        <description>For each PET/CT and PET assessment, the number of lesions detected by 68Ga-satoreotide trizoxetan and SoT (ceCT) were reported for each of the following anatomic sites; primary site of GEP-NET, lymph nodes, liver, axial/appendicular skeleton (bone) and lungs. The difference was calculated by number of lesions detected by 68Ga-satoreotide trizoxetan - number of lesions detected by ceCT scan. A positive difference indicates that more lesions were detected by 68Ga-satoreotide trizoxetan than by ceCT scan. A negative difference indicates that more lesions were detected by ceCT scan than by 68Ga-satoreotide trizoxetan. The difference in number of lesions for PET/CT and PET readings for the 5 anatomic sites results are presented by both peptide mass range and radioactivity dose range.</description>
        <time_frame>Day 1 and Days 16 to 22</time_frame>
        <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peptide Mass Dose Range 5-20 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg on Visit 2 (Day 1).</description>
          </group>
          <group group_id="O2">
            <title>Peptide Mass Dose Range 30-45 μg</title>
            <description>Subjects from Arms A, B and C who received an injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O3">
            <title>Radioactivity Dose Range 40-80 MBq</title>
            <description>Subjects from Arms A and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose of 40-80 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O4">
            <title>Radioactivity Dose Range 100-140 MBq</title>
            <description>Subjects from Arms A and B who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 100-140 MBq on either Visit 2(Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
          <group group_id="O5">
            <title>Radioactivity Dose Range 160-200 MBq</title>
            <description>Subjects from Arms B and C who received an injection of 68Ga-satoreotide trizoxetan with a radioactivity dose range of 160-200 MBq on either Visit 2 (Day 1) or on Visit 3 (Days 16-22).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Compared to Lesions Detected by SoT Presented by Peptide Mass and Radioactivity Dose Ranges</title>
          <description>For each PET/CT and PET assessment, the number of lesions detected by 68Ga-satoreotide trizoxetan and SoT (ceCT) were reported for each of the following anatomic sites; primary site of GEP-NET, lymph nodes, liver, axial/appendicular skeleton (bone) and lungs. The difference was calculated by number of lesions detected by 68Ga-satoreotide trizoxetan - number of lesions detected by ceCT scan. A positive difference indicates that more lesions were detected by 68Ga-satoreotide trizoxetan than by ceCT scan. A negative difference indicates that more lesions were detected by ceCT scan than by 68Ga-satoreotide trizoxetan. The difference in number of lesions for PET/CT and PET readings for the 5 anatomic sites results are presented by both peptide mass range and radioactivity dose range.</description>
          <population>Results are presented for the PP population which consisted of the first 24 randomised subjects who could be assessed and for whom no major protocol violations/deviations impacting primary endpoint results occurred. Only subjects with data available were included in the analysis.</population>
          <units>Lesions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET/CT: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O3" value="0.5" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="-3" upper_limit="53"/>
                    <measurement group_id="O2" value="10.0" lower_limit="-5" upper_limit="75"/>
                    <measurement group_id="O3" value="5.5" lower_limit="-5" upper_limit="75"/>
                    <measurement group_id="O4" value="8.0" lower_limit="-1" upper_limit="19"/>
                    <measurement group_id="O5" value="10.0" lower_limit="-3" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-3" upper_limit="11"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-3" upper_limit="11"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-3" upper_limit="7"/>
                    <measurement group_id="O5" value="1.0" lower_limit="-2" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="43"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1" upper_limit="31"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0" upper_limit="43"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET/CT: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Primary Site</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O3" value="1.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O4" value="0.5" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O5" value="1.0" lower_limit="-1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="-3" upper_limit="58"/>
                    <measurement group_id="O2" value="6.0" lower_limit="-8" upper_limit="60"/>
                    <measurement group_id="O3" value="4.5" lower_limit="-8" upper_limit="60"/>
                    <measurement group_id="O4" value="6.0" lower_limit="-2" upper_limit="25"/>
                    <measurement group_id="O5" value="8.0" lower_limit="-3" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="-2" upper_limit="18"/>
                    <measurement group_id="O2" value="3.5" lower_limit="-2" upper_limit="13"/>
                    <measurement group_id="O3" value="4.0" lower_limit="-1" upper_limit="8"/>
                    <measurement group_id="O4" value="2.0" lower_limit="-2" upper_limit="18"/>
                    <measurement group_id="O5" value="5.0" lower_limit="-2" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0" upper_limit="31"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="34"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0" upper_limit="31"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET: Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1" upper_limit="4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O5" value="2.0" lower_limit="-1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events (AEs) were recorded from Day 1 up to 14 days after the last dose of investigational imaging product (up to 36 days overall).</time_frame>
      <desc>All subjects included in the Safety Population analysis received 2 injections of 68Ga-satoreotide trizoxetan during the study. AEs were allocated to each combination of injected peptide/radioactivity dose range according to the following rule: AEs were allocated to the last dose of 68Ga-satoreotide trizoxetan received, based on AE start date/time.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: 5-20 μg/40-80 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 40-80 MBq on Visit 2 (Day 1).</description>
        </group>
        <group group_id="E2">
          <title>Arm A: 30-45 μg/100-140 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 100-140 MBq on Visit 3 (Days 16 to 22).</description>
        </group>
        <group group_id="E3">
          <title>Arm B: 5-20 μg/100-140 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 100-140 MBq on Visit 2 (Day 1).</description>
        </group>
        <group group_id="E4">
          <title>Arm B: 30-45 μg/160-200 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 160-200 MBq on Visit 3 (Days 16 to 22).</description>
        </group>
        <group group_id="E5">
          <title>Arm C: 5-20 μg/160-200 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 5-20 μg and a radioactivity range of 160-200 MBq.</description>
        </group>
        <group group_id="E6">
          <title>Arm C: 30-45 μg/40-80 MBq</title>
          <description>Subjects received a single i.v. injection of 68Ga-satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity range of 40-80 MBq on Visit 3 (Days 16 to 22).</description>
        </group>
        <group group_id="E7">
          <title>Overall</title>
          <description>Total number of AEs experienced across all Arms.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In each injected peptide/radioactivity dose combination for outcome measures 1, 3 and 6, the number of subjects with lesions in the primary site of GEP-NET, bone and lung was too small (0 to 3) to allow for a meaningful interpretation of the results. Similarly, in each category of peptide mass range and radioactivity dose range for outcome measures 2, 4 and 7, the number of subjects with lesions in bone and lung was too small (0 to 2) to allow for a meaningful interpretation of the results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ipsen Medical Director</name_or_title>
      <organization>Ipsen</organization>
      <phone>See email</phone>
      <email>clinical.trials@ipsen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

